{'Year': '2024', 'Month': 'Feb'}
Most patients with disorders of gut-brain interaction receive pharmacotherapy with major or moderate drug-gene interactions.
How variations predicted by pharmacogenomic testing to alter drug metabolism and therapeutic response affect outcomes for patients with disorders of gut- brain interaction is unclear.